Expert Review of Hematology最新文献_第9页

The linkage between hemoglobin-to-red blood cell distribution width ratio and osteoarthritis: a study based on the national health and nutrition examination survey. 血红蛋白与红细胞分布宽度比与骨关节炎的关系：基于全国健康与营养检查调查的研究。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-02-24 DOI: 10.1080/17474086.2026.2634991

Wuyang Zhou, Guanfeng Lu, Jing Wang, Shujuan Fan, Gang Fang

{"title":"The linkage between hemoglobin-to-red blood cell distribution width ratio and osteoarthritis: a study based on the national health and nutrition examination survey.","authors":"Wuyang Zhou, Guanfeng Lu, Jing Wang, Shujuan Fan, Gang Fang","doi":"10.1080/17474086.2026.2634991","DOIUrl":"10.1080/17474086.2026.2634991","url":null,"abstract":"Background: Inflammation is crucial in osteoarthritis (OA) pathogenesis. The hemoglobin-to-red cell distribution width ratio (HRR), an emerging inflammatory marker, remains unclear regarding its connection with OA.Research design and methods: This study was based on National Health and Nutrition Examination Survey (NHANES) data spanning 2003-2016, covering 13,453 participants. Weighted logistic regression assessed the HRR-OA association. Subgroup and interaction analyses evaluated differences across populations.Results: After adjusting for all confounders in the model, a negative association between HRR and OA (Odds Ratio (OR) = 0.56, 95% Confidence Interval (CI): 0.34-0.93) was detected. Compared to the lowest quartile, the third and highest HRR quartiles were associated with 23% (OR = 0.77) and 34% (OR = 0.66) lower OA odds, respectively. This inverse association was stronger in subgroups including individuals ≥65 years, males, and those widowed/divorced/separated. Marital status showed a significant interaction effect.Conclusions: HRR is negatively correlated with the risk of OA and may serve as a potential relevant biological marker. Future studies could further confirm the linkage between HRR and OA by integrating imaging assessments with clinical evaluations.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"571-577"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147276304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing the impact of air pollution on anemia: a comprehensive review and meta-analysis. 评估空气污染对贫血的影响：一项综合综述和荟萃分析。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-03-13 DOI: 10.1080/17474086.2026.2643325

Chi-Thien Dinh, Yueh-Lun Lee, Li-Te Chang, Ta-Yuan Chang, Kian Fan Chung, Kang-Yun Lee, Jer-Hwa Chang, Hsiao-Chi Chuang

{"title":"Assessing the impact of air pollution on anemia: a comprehensive review and meta-analysis.","authors":"Chi-Thien Dinh, Yueh-Lun Lee, Li-Te Chang, Ta-Yuan Chang, Kian Fan Chung, Kang-Yun Lee, Jer-Hwa Chang, Hsiao-Chi Chuang","doi":"10.1080/17474086.2026.2643325","DOIUrl":"10.1080/17474086.2026.2643325","url":null,"abstract":"Introduction: Air pollution and household fuel use may impair hematologic health through inflammation and oxidative stress. We synthesized evidence on associations of ambient/household air pollution with anemia risk and erythrocyte indices.Methods: We searched PubMed, Embase, and Web of Science (inception-27 September 2025). Two reviewers independently screened and extracted data, and assessed risk of bias using Joanna Briggs Institute checklists. Random-effects meta-analyses pooled risk ratios (RRs) per 10 µg/m3 for particulate matter with aerodynamic diameter ≤10 µm (PM10), ≤2.5 µm (PM2.5), and nitrogen dioxide (NO2), and by household fuel type.Results: Thirty-six studies were included. Each 10 µg/m3 increase in PM2.5 and NO2 was associated with higher anemia risk (RR 1.200, 95% CI 1.041-1.384, I2 98.2%; RR 1.127, 95% CI 1.025-1.241, I2 98.0%). Solid and biomass fuel increased anemia risk (RR 1.143, 95% CI 1.027-1.274, I2 82.9%; RR 1.271, 95% CI 1.050-1.539, I2 91.7%). PM10 was associated with lower hemoglobin (0.074 g/dL, 95% CI -0.124 to -0.023, I2 90.7%). Effects were generally stronger in males and in low- and middle-income countries.Conclusions: Ambient and household air pollution are associated with increased anemia risk and reductions in hemoglobin; high heterogeneity and observational designs limit causal inference.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"529-538"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond linearity and static risk: re-evaluating core prognostic factors in diffuse large B-cell lymphoma. 超越线性和静态风险：重新评估弥漫性大b细胞淋巴瘤的核心预后因素。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-03-12 DOI: 10.1080/17474086.2026.2643330

Rashad Ismayilov, Murat Ozdede, Yahya Buyukasik

{"title":"Beyond linearity and static risk: re-evaluating core prognostic factors in diffuse large B-cell lymphoma.","authors":"Rashad Ismayilov, Murat Ozdede, Yahya Buyukasik","doi":"10.1080/17474086.2026.2643330","DOIUrl":"10.1080/17474086.2026.2643330","url":null,"abstract":"Background: This study challenges the static and linear assumptions of traditional prognostic models for diffuse large B-cell lymphoma (DLBCL), such as the International Prognostic Index (IPI).Research design and methods: Analyzing 664 DLBCL patients treated with R-CHOP, the research explored the time-dependent and nonlinear effects of established risk factors.Results: While the IPI maintained strong overall prognostic stability, its individual components exhibited dynamic behavior. ECOG performance score, beta-2 microglobulin (β2 M), and lactate dehydrogenase (LDH) were key predictors of early mortality, with their influence diminishing over time. Conversely, the importance of Ann Arbor stage and extranodal involvement grew, identifying them as markers of later risk. Notably, the study found a resurgence in the predictive power of β2 M after two years. Furthermore, restricted cubic spline modeling revealed significant nonlinear relationships between overall survival and age, LDH, and β2 M (all p < 0.001 for nonlinearity).Conclusions: The prognostic impact of baseline factors in DLBCL follows dynamic and nonlinear trajectories, challenging the one-size-fits-all approach of current risk scores. Future models should incorporate these temporal dynamics to provide a more accurate, personalized risk assessment.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"563-570"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of gene polymorphisms in the susceptibility and therapeutic response of chronic immune thrombocytopenic purpura. 基因多态性在慢性免疫性血小板减少性紫癜易感性和治疗反应中的作用。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-04-09 DOI: 10.1080/17474086.2026.2636163

Mohammad Reza Moghaddasnejad, Mojtaba Aghaei, Najmaldin Saki

{"title":"The role of gene polymorphisms in the susceptibility and therapeutic response of chronic immune thrombocytopenic purpura.","authors":"Mohammad Reza Moghaddasnejad, Mojtaba Aghaei, Najmaldin Saki","doi":"10.1080/17474086.2026.2636163","DOIUrl":"10.1080/17474086.2026.2636163","url":null,"abstract":"Introduction: Chronic immune thrombocytopenic purpura (cITP) is a prolonged autoimmune disorder characterized by persistent low platelet counts and the presence of anti-platelet antibodies. The disease exhibits heterogeneity in severity and therapeutic response, which complicates management and underscores the importance of identifying predictive biomarkers.Areas covered: This review examines gene polymorphisms in cytokines, immune receptors, and transcription factors associated with susceptibility to cITP. Additionally, this study highlights the impact of specific genetic polymorphisms in the IL6, IL10, CXCL12, FCGR, TLR4, ICOS, DNAM1, and ABCB1 genes on the response to treatment in patients with cITP. A comprehensive search of PubMed, Scopus, and Web of Science from 1998 to July 2025 was performed to include all relevant studies.Expert opinion: Genetic profiling has the potential to refine our understanding of cITP and guide clinical decision-making. Advances in this field may enable the development of personalized medicine approaches, where genetic information is integrated into diagnostic and therapeutic strategies to optimize patient outcomes.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"507-516"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematologic disorders in pregnancy: the role of the complement system. 妊娠期血液病：补体系统的作用。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-03-16 DOI: 10.1080/17474086.2026.2634997

Charlotte M Story, Shruti Chaturvedi, Gloria F Gerber

{"title":"Hematologic disorders in pregnancy: the role of the complement system.","authors":"Charlotte M Story, Shruti Chaturvedi, Gloria F Gerber","doi":"10.1080/17474086.2026.2634997","DOIUrl":"10.1080/17474086.2026.2634997","url":null,"abstract":"Introduction: Complement homeostasis is essential for healthy pregnancy and excessive complement activation can lead to devastating maternal and fetal outcomes by precipitating or worsening complement-mediated disorders. This review summarizes changes in complement regulation during pregnancy, management considerations in paroxysmal nocturnal hemoglobinuria (PNH), thrombotic microangiopathies (TMA), and antiphospholipid syndrome (APS), and emerging evidence regarding the role of complement in the severe hypertensive disorders of pregnancy (preeclampsia with severe features, HELLP syndrome).Areas covered: This is an expert narrative review. Articles were selected based on the authors' subject-matter expertise to highlight key studies, concepts, and areas of active investigation, rather than through a systematic literature search strategy. Relevant articles on the role of complement in pregnancy are summarized and critiqued. We review pregnancy outcomes and management in PNH, TMA, and APS. We prioritize review of clinical trials, registry or systematic review studies, and novel case reports utilizing complement inhibitors during pregnancy.Expert opinion: Complement inhibitors have greatly improved maternal morbidity and mortality in PNH and complement-mediated TMAs. Establishing functional biomarkers of complement activity in pregnancy, defining metrics for prompt use of complement inhibitors in TMAs, and clinical trials of complement inhibition for obstetric APS and hypertensive disorders of pregnancy are urgently needed.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"491-506"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13370807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia. ≥65岁高龄慢性淋巴细胞白血病患者一线布鲁顿酪氨酸激酶抑制剂的现实世界治疗利用模式、停药和医疗资源利用

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-02-14 DOI: 10.1080/17474086.2026.2628534

Sikander Ailawadhi, Swetha Challagulla, Po-Ya Chuang, Wesley Furnback, Keri Yang

{"title":"Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia.","authors":"Sikander Ailawadhi, Swetha Challagulla, Po-Ya Chuang, Wesley Furnback, Keri Yang","doi":"10.1080/17474086.2026.2628534","DOIUrl":"10.1080/17474086.2026.2628534","url":null,"abstract":"Background: Chronic lymphocytic leukemia (CLL) commonly affects older patients, who often endure greater health disparities and treatment burdens. This study assessed treatment utilization patterns, discontinuation, and healthcare resource utilization (HCRU) of first-line (1L) use of Bruton tyrosine kinase inhibitors (BTKis) in elderly patients with CLL.Research design and methods: A retrospective observational study using the Symphony Integrated Dataverse identified CLL patients aged ≥65 years initiating a 1L BTKi (zanubrutinib, acalabrutinib, ibrutinib; 01/2022-11/2024). Baseline characteristics and outcomes were reported for each BTKi. Treatment discontinuation rate was estimated at 3, 4, 5, 6, 12, 18, and 24 months, and by time to discontinuation (TTD), using Kaplan-Meier method. HCRU (outpatient, inpatient, and other services) was evaluated as per patient per year (PPPY).Results: A total of 5,344 patients ≥65 years were included (acalabrutinib = 2,662; zanubrutinib = 1,577; ibrutinib = 1,105). Baseline characteristics were similar across each BTKi. Zanubrutinib had the longest median TTD overall (zanubrutinib: 22.8 months, acalabrutinib: 17.4 months, ibrutinib: 14.3 months; p < .0001). Average outpatient visits PPPY were lowest for zanubrutinib (zanubrutinib: 9.7, acalabrutinib: 10.9, ibrutinib: 11.5; p = .0018).Conclusions: This real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU than acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"539-546"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of restrictive and liberal blood transfusion in critically ill adults: a meta-analysis and comprehensive review. 危重成人限制性和自由输血的比较：荟萃分析和综合评价。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-03-04 DOI: 10.1080/17474086.2026.2613264

Xinying Quan, Yao Pu, Keming Xia

{"title":"Comparison of restrictive and liberal blood transfusion in critically ill adults: a meta-analysis and comprehensive review.","authors":"Xinying Quan, Yao Pu, Keming Xia","doi":"10.1080/17474086.2026.2613264","DOIUrl":"10.1080/17474086.2026.2613264","url":null,"abstract":"Introduction: Faced with a shortage of blood sources, clinicians have been striving to utilize blood judiciously for critically ill patients. Although some researchers have attempted to explore this issue, there is still no consensus on its applicability in different situations. Therefore, we first conducted a systematic review and meta-analysis by category, providing a more scientific and reasonable basis for clinical treatment decisions.Methods: We searched databases up to 11 June 2025, including PubMed, EmBase, Cochrane, and Web of Science. The participants were critically ill adult patients. We collected and grouped different hemoglobin (Hb) thresholds during restricted and liberal blood transfusions. The primary outcomes encompassed mortality rate, length of hospital stay, and adverse reactions.Results: 30,943 critically ill patients were included in 33 studies. Patients with closed head injuries in the restricted group had a higher risk of mortality (RR = 1.78, 95% CI: 1.48-2.15), particularly those with concomitant subarachnoid hemorrhage; Mortality rates were also higher among cardiovascular patients over the age of 60 (RR = 1.54, 95% CI = 1.05-2.24); Tertiary hospitals were found to facilitate patient recovery.Conclusions: Critical patients with closed brain injuries and comorbidities, as well as those over 60 years old with cardiovascular diseases, may benefit from high-threshold liberal strategies. The protocol was registered on PROSPERO with the ID of CRD42024606971.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"517-528"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frailty and chronic lymphocytic leukemia: navigating challenges to improve outcomes. 虚弱和慢性淋巴细胞白血病：导航挑战，以改善结果。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-03-26 DOI: 10.1080/17474086.2026.2647258

Stefano Molica

{"title":"Frailty and chronic lymphocytic leukemia: navigating challenges to improve outcomes.","authors":"Stefano Molica","doi":"10.1080/17474086.2026.2647258","DOIUrl":"10.1080/17474086.2026.2647258","url":null,"abstract":"Introduction: Targeted therapies have improved both efficacy and safety profiles in chronic lymphocytic leukemia (CLL). Nevertheless, they present novel challenges in patient selection, particularly within aging populations wherein individuals aged over 80 years remain underrepresented in clinical trials.This review examines how frailty and biological aging intersect with CLL to inform risk stratification, treatment decisions, and supportive care.Areas covered: We conducted a systematic literature search of PubMed and MEDLINE to identify studies including frail patients with CLL. Key findings indicate that frailty affects approximately 20% of patients with CLL. Alongside preexisting comorbidities, pre-malignant aging processes-such as clonal hematopoiesis of indeterminate potential (CHIP) and monoclonal B-cell lymphocytosis (MBL)-contribute to an underlying frailty predisposition, which is exacerbated by CLL. Comprehensive geriatric assessment (CGA) remains the gold standard for frailty evaluation, yet its implementation in routine clinical practice is limited by time constraints and resource demands. As frailty represents a dynamic state, initial assessments should be augmented by serial monitoring to inform adjustments in therapeutic intensity and supportive care.Expert opinion: Personalized therapy planning that optimizes efficacy while mitigating toxicity in elderly/frail patients should be pursued. Future trials should ideally compare fixed-duration versus continuous therapy in well-characterized older or frail cohorts, with explicit objectives to enhance real-world applicability.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"465-473"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Per aspera ad astra": the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high-dose therapy. “完全不同”：葡萄糖苷酶对高剂量治疗后延迟甲氨蝶呤消除的改善管理的变革性贡献。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-05-01 Epub Date: 2026-03-20 DOI: 10.1080/17474086.2026.2643326

Nicolò Peccatori, Stefan Schwartz, Carmelo Rizzari

{"title":"\"Per aspera ad astra\": the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high-dose therapy.","authors":"Nicolò Peccatori, Stefan Schwartz, Carmelo Rizzari","doi":"10.1080/17474086.2026.2643326","DOIUrl":"10.1080/17474086.2026.2643326","url":null,"abstract":"Introduction: High-dose methotrexate (HDMTX) is an important therapeutic tool for various malignancies; its use can be associated with severe treatment-emergent toxicities, particularly nephrotoxicity. These can disrupt anticancer treatment and increase morbidity and mortality. Glucarpidase (carboxypeptidase G2), a recombinant bacterial enzyme, rapidly converts toxic levels of circulating methotrexate (MTX) into nontoxic metabolites in patients with delayed MTX elimination and/or at risk of MTX toxicity. The reduction in MTX-associated toxicity and mortality can improve patients' outcomes. MTX elimination prevents the progression of renal toxicity and may minimize treatment disruptions by facilitating resumption of anticancer treatment, including HDMTX rechallenge. Currently, glucarpidase is underused in clinical practice, partly due to accessibility issues and uncertainty regarding treatment timings.Areas covered: This review aims to provide clarity into the optimal application of glucarpidase by exploring its history and development, reviewing the clinical benefits reported in clinical trials and from real-world experiences, and critically considering recommendations for its administration.Expert opinion: Glucarpidase is an invaluable tool in the management of MTX toxicity, allowing rapid and effective reduction of MTX toxic drug levels, especially in patients with compromised renal function. To update glucarpidase administration algorithms, research is needed to evaluate its efficacy in patients with moderate MTX elevations.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"475-489"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen. Linvoseltamab， bcma定向CD3 t细胞参与治疗多发性骨髓瘤：通过反应适应给药方案的以患者为中心的选择？

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-04-01 Epub Date: 2026-03-04 DOI: 10.1080/17474086.2026.2634283

Jacob A Lowy, Michael F Rogers, Zachary M Avigan, Marcus S Flores, Marina Samuel, Mohammad A Rattu, Joshua Richter

{"title":"Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen.","authors":"Jacob A Lowy, Michael F Rogers, Zachary M Avigan, Marcus S Flores, Marina Samuel, Mohammad A Rattu, Joshua Richter","doi":"10.1080/17474086.2026.2634283","DOIUrl":"10.1080/17474086.2026.2634283","url":null,"abstract":"Introduction: Despite advances in the treatment of multiple myeloma (MM), there remains a significant need for new modalities, mechanisms of action (MOA), and combinations to achieve durable remissions. Bispecific T-cell engagers (BiTEs), particularly those targeting B-cell maturation antigen (BCMA), have demonstrated robust outcomes in patients with progression through multiple lines of therapy. Linvoseltamab, a novel BCMAxCD3 bispecific, was recently the FDA and EMA-approved based on the LINKER-MM1 trial for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who have progressed beyond four lines of therapy.Areas covered: We will discuss the MOA, pharmacokinetics, efficacy, and toxicity of linvoseltamab compared with other approved BiTEs. We will highlight linvoseltamab's patient-centric dosing regimen and improved side effect profile, and we will review published indirect efficacy comparisons with other approved BCMA directed therapies.Expert opinion: Linvoseltamab is the fourth FDA approved bispecific antibody for the treatment of RRMM in patients who have received four or more lines of therapy. Cross-trial comparisons ave suggested that linvoseltamab has comparable to slightly better efficacy compared with other agents. Linvoseltamab offers an optimized dosing regimen with a favorable CRS profile. Further real-world data are needed to understand linvoseltamab's role within the MM treatment paradigm.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"361-372"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0